COPD exacerbation phenotypes: The next frontier by Moran, A, Pavord, I

Antimicrobial peptides in inflammatory phenotypes of COPD by Cane, J, Thulborn, S, Piper, S, Finch, D, Bafadhel, M

Are COPD and cardiovascular disease fundamentally intertwined? by Bafadhel, M, Russell, R

“…<p>Elastin loss may be the link between COPD and cardiovascular disease http://ow.ly/YVwFC</p>…”

What will happen in the world of COPD 2030? by Russell, REK, Bafadhel, M

“…We live in a world of relentless rapid change in modern medicine and our approach to our patients with chronic diseases such as chronic obstructive pulmonary disease (COPD) will need to evolve at speed. This review looks at what may occur in society and medicine that will influence the way we manage COPD. …”

Eosinophils in COPD: just another biomarker? by Bafadhel, M, Pavord, I, Russell, R

“…Eosinophils have been found in the airways, tissues, and circulation of patients with COPD, during both stable disease and exacerbations. …”

Antibiotic prevention of acute exacerbations of COPD. by Chapman, S

Symptomatic COPD: is it time for triple therapy? by Bafadhel, M

Lung microbiome dynamics in COPD exacerbations by Wang, Z, Bafadhel, M, Haldar, K, Spivak, A, Mayhew, D, Miller, BE, Tal-Singer, R, Johnston, SL, Ramsheh, MY, Barer, MR, Brightling, CE, Brown, JR

“…Increasing evidence suggests that the lung microbiome plays an important role in chronic obstructive pulmonary disease (COPD) severity. However, the dynamics of the lung microbiome during COPD exacerbations and its potential role in disease aetiology remain poorly understood. …”

Determinants of underdiagnosis of COPD in national and international surveys by Lamprecht, B, Soriano, JB, Studnicka, M, Kaiser, B, Vanfleteren, LE, Gnatiuc, L, Burney, P, Miravitlles, M, García-Rio, F, Akbari, K, Ancochea, J, Menezes, AM, Perez-Padilla, R, Montes de Oca, M, Torres-Duque, CA, Caballero, A, González-García, M, Buist, S

“…<p><strong>Background:</strong> COPD ranks within the top three causes of mortality in the global burden of disease, yet it remains largely underdiagnosed. …”

Covid-19 and COPD: A personal reflection by Russell, R

The role of CT scanning in multidimensional phenotyping of COPD. by Bafadhel, M, Umar, I, Gupta, S, Raj, J, Vara, D, Entwisle, J, Pavord, I, Brightling, C, Siddiqui, S

“…BACKGROUND: COPD is a heterogeneous disease characterized by airflow obstruction and diagnosed by lung function. …”

The Lancet COPD Commission: broader questions remain by Petousi, N, Pavord, ID, Couillard, S

Inhaled corticosteroids in COPD (multiple letters) [1] by Hart, S, Confalonieri, M, Spanevello, A, Tsang, K, Brightling, C, Pavord, I

COPD exacerbations: transforming outcomes through research by Hurst, JR, Bafadhel, M, Bolton, CE, Quint, JK, Sapey, E, Wilkinson, TMA

COPD and Hepatitis C [4] (multiple letters) by Pavord, I, Birring, S, Kanazawa, H

M-health for long-term management of COPD by Tarassenko, L, Velardo, C, Shah, A, Gibson, O, Clifford, G, Heneghan, C, Rutter, H, Farmer, A

mHealth mood monitoring for people with COPD by Whelan, M, Velardo, C, Rutter, H, Tarassenko, L, Farmer, A

“…Background: Co-morbid anxiety and depression can add to the complexity of chronic obstructive pulmonary disease (COPD). While digital health technologies for people with COPD support monitoring of vital signs (including oxygen saturation and pulse), mood is not routinely monitored even though it could support self-management. …”

Blood eosinophil levels as a biomarker in COPD by Brusselle, G, Pavord, I, Landis, S, Pascoe, S, Lettis, S, Morjaria, N, Barnes, N, Hilton, E

“…Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients respond differently to treatment. …”

Seasonality of eosinophilic and non-eosinophilic exacerbations of COPD by Barker, R, Shrimanker, R, Russell, R, Fenton-Woods, J, Jones, C, Smith, L, Johnson, M, Pavord, I

“…Patients presenting with an exacerbation of COPD and a peripheral blood eosinophil count &gt;=2% have a better response to oral cortico-steroids, suggesting that stratification by this biomarker identifies a pathologically distinct phenotype and might have clinical value.3 We have tested the hypothesis that the eosinophilic and non-eosinophilicexacerbations of COPD have different seasonality using a large dataset of patents admitted to Kings College Hospital (KCH) with AECOPD over 10-years.…”

Home warmth and health status of COPD patients. by Osman, L, Ayres, J, Garden, C, Reglitz, K, Lyon, J, Douglas, J

“…Is health status of patients with Chronic Obstructive Pulmonary Disease (COPD) associated with maintaining this level of warmth in their homes? …”